- Pretomanid
-
-
2026-09-17
- CAS:187235-37-6
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Pretomanid.
-
-
2026-09-17
- CAS:187235-37-6
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Pretomanid
-
-
2026-05-18
- CAS:187235-37-6
- Min. Order: 1kg
- Purity: 98%
|
| | Pretomanid Basic information |
| Product Name: | Pretomanid | | Synonyms: | PA 824;(S)-PA 824;(6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine;(S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine;5H-IMidazo[2,1-b][1,3]oxazine, 6,7-dihydro-2-nitro-6-[[4-(trifluoroMethoxy)phenyl]Methoxy]-, (6S)-;(S)-6-(4-(trifluoromethoxy)benzyloxy)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine;(6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine PA-824;EOS-60675 | | CAS: | 187235-37-6 | | MF: | C14H12F3N3O5 | | MW: | 359.26 | | EINECS: | 1533716-785-6 | | Product Categories: | Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors | | Mol File: | 187235-37-6.mol |  |
| | Pretomanid Chemical Properties |
| Melting point | 149-150℃ | | Boiling point | 462.3±55.0 °C(Predicted) | | density | 1.58 | | storage temp. | -20°C | | solubility | DMSO (Slightly), Methanol (Slightly) | | pka | -0.67±0.40(Predicted) | | form | powder | | color | white to brown | | Optical Rotation | [α]/D -40 to -48°, c = 1 in methanol | | InChI | InChI=1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1 | | InChIKey | ZLHZLMOSPGACSZ-NSHDSACASA-N | | SMILES | O1C[C@@H](OCC2=CC=C(OC(F)(F)F)C=C2)CN2C=C([N+]([O-])=O)N=C12 |
| WGK Germany | WGK 3 | | HS Code | 2933992000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | Pretomanid Usage And Synthesis |
| Uses | A novel anti-tuberculosis drug. | | Biological Activity | pa-824, a bicyclic nitroimidazoles, is an anti-tuberculosis (tb) agent that exerts potent in vitro activity against mycobacterium tuberculosis with the minimal inhibition concentration (mic) ranging from 0.015 μg/ml to 0.25 μg/ml and remains actively against a wide range of isolates that are resistant to commonly used anti-tb agents leading to its successful application in the treatment of tb [1].pa-824 has been found to exhibit bactericidal activity against replicating bacilli and non-replicating bacilli under hypoxic or prolonged culture conditions in a dose dependent fashion through two possible mechanisms, which include pa-824 induced inhibition of ketomycolate synthesis and pa-824 mediated donation of nitric oxide during enzymatic nitro-reduction [1]. | | Biochem/physiol Actions | PA-824 is an anti-tuberculosis drug. | | Synthesis | Pretomanid can be produced as follow
 | | references | [1] ahmad z, peloquin ca, singh rp, derendorf h, tyagi s, ginsberg a, grosset jh, nuermberger el. pa-824 exhibits time-dependent activity in a murine model of tuberculosis. antimicrob agents chemother. 2011 jan;55(1):239-45. doi: 10.1128/aac.00849-10. epub 2010 oct 11. |
| | Pretomanid Preparation Products And Raw materials |
|